VYNFINIT® (Vintafolide) Cancer*
Designed to target the folate receptor to deliver potent chemotherapy
Vynfinit® (Vintafolide) delivers a potent vinca alkaloid chemotherapy directly to cancer cells by targeting the folate receptor expressed on cancer cells, but not on most normal cells. Approximately 80–90% of ovarian and lung cancers express the receptor, as do many other types of cancer. Folate receptor status is determined by a Folcepri® (99mTc-etarfolatide) scan.
Non-small cell lung cancer:
- Vynfinit® is being investigated in a Phase 2b study named TARGET in patients with non-small cell lung cancer (NSCLC). Results are pending.
- Vynfinit® is being investigated in a Phase 1 study in patients with advanced cancers.
Future clinical trials:
- Vynfinit® will be evaluated in women with triple-negative breast cancer in a Phase 2b study scheduled to begin in 2014.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.